Citation | Ye, XY; Chen, SY; Wu, S; Yoon, DS; Wang, H; Hong, Z; O'Connor, SP; Li, J; Li, JJ; Kennedy, LJ; Walker, SJ; Nayeem, A; Sheriff, S; Camac, DM; Ramamurthy, V; Morin, PE; Zebo, R; Taylor, JR; Morgan, NN; Ponticiello, RP; Harrity, T; Apedo, A; Golla, R; Seethala, R; Wang, M; Harper, TW; Sleczka, BG; He, B; Kirby, M; Leahy, DK; Li, J; Hanson, RL; Guo, Z; Li, YX; DiMarco, JD; Scaringe, R; Maxwell, B; Moulin, F; Barrish, JC; Gordon, DA; Robl, JA Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11?-Hydroxysteroid Dehydrogenase Type 1 Inhibitor. J Med Chem60:4932-4948 (2017) [PubMed] Article |
---|
SMILES | OC1CN(C1)C(=O)CC1(C2CC3CC1CC(C3)(C2)C#N)c1ccc(F)cc1 |TLB:17:15:8.9.10:12,7:8:14.17.15:10.11.12,7:8:12:14.15.16,THB:17:9:12:14.15.16,16:15:8:10.11.12,16:11:8:14.17.15,18:15:8:10.11.12,18:15:8.9.10:12,20:8:14.17.15:10.11.12,20:8:12:14.15.16,(34.25,-39.18,;34.73,-37.71,;34.04,-36.34,;35.41,-35.64,;36.11,-37.02,;35.89,-34.17,;34.64,-33.26,;37.36,-33.7,;38.51,-34.73,;40,-34.31,;40,-32.72,;41.04,-31.49,;39.7,-31.97,;39.71,-33.45,;41.03,-33.94,;42.43,-33.6,;42.45,-32.07,;41.42,-34.88,;43.96,-33.54,;45.5,-33.47,;38.49,-36.27,;37.15,-37.02,;37.13,-38.56,;38.46,-39.34,;38.44,-40.89,;39.8,-38.58,;39.81,-37.05,)| |